Antifungal Efficacy of an Intravenous Formulation Containing Monomeric Amphotericin B, 5-Fluorocytosine, and Saline for Sodium Supplementation

[1]  G. Kwon,et al.  Reformulation of Fungizone by PEG-DSPE Micelles: Deaggregation and Detoxification of Amphotericin B , 2016, Pharmaceutical Research.

[2]  J. Sobel,et al.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  J. Sobel,et al.  Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  S. Katiyar,et al.  Flucytosine Antagonism of Azole Activity versus Candida glabrata: Role of Transcription Factor Pdr1 and Multidrug Transporter Cdr1 , 2013, Antimicrobial Agents and Chemotherapy.

[5]  G. Kwon,et al.  Amphotericin B/Sterol Co-loaded PEG-Phospholipid Micelles: Effects of Sterols on Aggregation State and Hemolytic Activity of Amphotericin B , 2012, Pharmaceutical Research.

[6]  Daniel S. Palacios,et al.  Amphotericin primarily kills yeast by simply binding ergosterol , 2012, Proceedings of the National Academy of Sciences.

[7]  N. Davies,et al.  Pharmacokinetics and nephrotoxicity of amphotericin B-incorporated poly(ethylene glycol)-block-poly(N-hexyl stearate l-aspartamide) micelles. , 2011, Journal of pharmaceutical sciences.

[8]  J. Sobel,et al.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  D. Andes,et al.  Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications , 2008, Antimicrobial Agents and Chemotherapy.

[10]  R. Drew,et al.  Antifungal serum concentration monitoring: an update. , 2007, The Journal of antimicrobial chemotherapy.

[11]  D. Denning,et al.  Flucytosine therapeutic monitoring: 15 years experience from the UK. , 2007, The Journal of antimicrobial chemotherapy.

[12]  T. Harrison,et al.  Oral versus Intravenous Flucytosine in Patients with Human Immunodeficiency Virus-Associated Cryptococcal Meningitis , 2006, Antimicrobial Agents and Chemotherapy.

[13]  Ana Espinel-Ingroff,et al.  Synergistic Activities of Fluconazole and Voriconazole with Terbinafine against Four Candida Species Determined by Checkerboard, Time-Kill, and Etest Methods , 2005, Antimicrobial Agents and Chemotherapy.

[14]  M. Ghannoum,et al.  Combination Treatment of Invasive Fungal Infections , 2005, Clinical Microbiology Reviews.

[15]  H. Guchelaar,et al.  An in vitro Study on the Active Conversion of Flucytosine to Fluorouracil by Microorganisms in the Human Intestinal Microflora , 2003, Chemotherapy.

[16]  G. Kwon,et al.  Amphotericin B encapsulated in micelles based on poly(ethylene oxide)-block-poly(L-amino acid) derivatives exerts reduced in vitro hemolysis but maintains potent in vivo antifungal activity. , 2003, Biomacromolecules.

[17]  A. V. van Kuilenburg,et al.  5‐fluorocytosine‐related bone‐marrow depression and conversion to fluorouracil: a pilot study , 2002, Fundamental & clinical pharmacology.

[18]  J. Rex,et al.  In Vitro Synergy of Caspofungin and Amphotericin B against Aspergillus and Fusarium spp , 2002, Antimicrobial Agents and Chemotherapy.

[19]  D. Bates,et al.  Mortality and costs of acute renal failure associated with amphotericin B therapy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  D. Andes,et al.  Pharmacodynamics of Amphotericin B in a Neutropenic-Mouse Disseminated-Candidiasis Model , 2001, Antimicrobial Agents and Chemotherapy.

[21]  G. Kwon,et al.  The effect of serum albumin on the aggregation state and toxicity of amphotericin B. , 2000, Journal of pharmaceutical sciences.

[22]  D. Andes,et al.  In Vivo Characterization of the Pharmacodynamics of Flucytosine in a Neutropenic Murine Disseminated Candidiasis Model , 2000, Antimicrobial Agents and Chemotherapy.

[23]  J. Morschhäuser,et al.  Molecular aspects of fluconazole resistance development in Candida albicans , 1999, Mycoses.

[24]  S Sardari,et al.  In vitro dissociation of antifungal efficacy and toxicity for amphotericin B-loaded poly(ethylene oxide)-block-poly(beta benzyl L aspartate) micelles. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[25]  Russell E. Lewis,et al.  Influence of Test Conditions on Antifungal Time-Kill Curve Results: Proposal for Standardized Methods , 1998, Antimicrobial Agents and Chemotherapy.

[26]  D S Burgess,et al.  Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test , 1996, Antimicrobial agents and chemotherapy.

[27]  M. Miyaji,et al.  Comparative studies on the postantifungal effect produced by the synergistic interaction of flucytosine and amphotericin B on Candida albicans , 1992, Mycopathologia.

[28]  J. Barwicz,et al.  Effects of the aggregation state of amphotericin B on its toxicity to mice , 1992, Antimicrobial Agents and Chemotherapy.

[29]  R. Branch,et al.  Effect of salt supplementation on amphotericin B nephrotoxicity. , 1991, Kidney international.

[30]  K. Yazawa,et al.  Turbidometric characterization of the postantifungal effect: comparative studies with amphotericin B, 5‐fluorocytosine and miconazole on Candida albicans , 1991, Mycoses.

[31]  G. Medoff,et al.  Structure-activity study of inhibition of amphotericin B (Fungizone) binding to sterols, toxicity to cells, and lethality to mice by esters of sucrose , 1991, Antimicrobial Agents and Chemotherapy.

[32]  J. Barwicz,et al.  The effect of surfactants on the aggregation state of amphotericin B. , 1990, Biochimica et biophysica acta.

[33]  L. Chan,et al.  Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. , 1990, Annals of internal medicine.

[34]  H. Gallis,et al.  Amphotericin B: 30 years of clinical experience. , 1990, Reviews of infectious diseases.

[35]  R. Branch,et al.  Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. , 1988, Archives of internal medicine.

[36]  I. Gruda,et al.  Effect of the aggregation state of amphotericin B on its interaction with ergosterol. , 1988, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[37]  R. Diasio,et al.  Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. , 1987, The American journal of medicine.

[38]  R. Diasio,et al.  Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora , 1986, Antimicrobial Agents and Chemotherapy.

[39]  F. Odds.  Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro , 1982, Antimicrobial Agents and Chemotherapy.

[40]  J. Bolard,et al.  Interaction between phospholipid bilayer membranes and the polyene antibiotic amphotericin B: lipid state and cholesterol content dependence. , 1980, Biochimica et biophysica acta.

[41]  J. Edwards,et al.  Synergism of amphotericin B and 5-fluorocytosine for candida species. , 1975, The Journal of infectious diseases.

[42]  G. Medoff,et al.  Synergistic Action of Amphotericin B and 5-Fluorocytosine Against Yeast-Like Organisms 1 , 1971, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[43]  J. Bartlett.  Amphotericin B: Time for a new “gold standard” , 2004 .

[44]  G. Sarosi,et al.  Further evidence for sequential action of amphotericin B and 5-fluorocytosine against Candida albicans. , 1982, Chemotherapy.

[45]  D. Schlessinger,et al.  Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B (yeast-membrane permeability-ribosomal RNA-eukaryotic cell-synergism). , 1972, Proceedings of the National Academy of Sciences of the United States of America.